Matthias Schwarz

USPTO Granted Patents = 35 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 8)

Average Co-Inventor Count = 5.7

ph-index = 8

Forward Citations = 158(Granted Patents)

Location History:

Glard, CH (2011 - 2012)
Gland (VD), CH (2012)
Geneve, CH (2009 - 2014)
Thonex, CH (2004 - 2015)
Geneva, CH (2006 - 2019)
Gland, CH (2012 - 2022)

Company Filing History:

Applied Research Systems Ars Holding N.v.

patents

4 out of 40

Laboratoires Serono S.a.

Years Active: 2004-2022

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11524003 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2022-12-13),

2. 11028054 - 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors (2021-06-08),

3. 10555934 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2020-02-11),

4. 10259795 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2019-04-16),

5. 9834528 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2017-12-05),

6. 9447055 - α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2016-09-20),

7. 9150561 - Thiazole derivatives and use thereof (2015-10-06),

8. 9150519 - 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis (2015-10-06),

9. 9006454 - Dihydroorotate dehydrogenase inhibitors (2015-04-14),

10. 8946227 - Piperazine derivatives and methods of use (2015-02-03),

11. 8841459 - 3-arylamino pyridine derivatives (2014-09-23),

12. 8802861 - Thiazole derivatives and use thereof (2014-08-12),

13. 8802703 - Arylamino N-heteraryl compounds as MEK inhibitors (2014-08-12),

14. 8796280 - 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors (2014-08-05),

15. 8524911 - 3-arylamino pyridine derivatives (2013-09-03),

Title: Innovations of Matthias Schwarz

Introduction

Matthias Schwarz, based in Gland, Switzerland, is a prolific inventor with a remarkable portfolio consisting of 35 patents. His contributions to the field of pharmaceuticals and therapeutic compounds are particularly noteworthy.

Latest Patents

Schwarz's latest inventions include:

1. **Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof** - This invention provides alpha-amino esters of a hydroxypropylthiazolidine carboxamide derivative that can inhibit the prostaglandin F receptor. The innovation also introduces methods for treating disorders like preterm labor during the early gestational stage through the administration of these compounds.

2. **1,4,6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors** - This patent presents derivatives that may serve as effective dihydroorotate dehydrogenase (DHODH) inhibitors. These compounds are therapeutically useful in treating diseases where DHODH inhibition is advantageous, alongside methods for their synthesis and pharmaceutical formulations containing these compounds.

Career Highlights

Throughout his career, Matthias Schwarz has made significant contributions while working for renowned companies such as Merck Serono S.A. and Applied Research Systems Ars Holding N.V. His expertise in drug development and innovative solutions has helped advance the pharmaceutical sciences.

Collaborations

Schwarz has collaborated with other professionals in the field, including notable coworkers like Anna Quattropani and Patrick Naxos Page. These collaborations have furthered the development of groundbreaking inventions and enhanced the potential for innovative treatments.

Conclusion

With 35 patents to his name, Matthias Schwarz continues to be a pivotal figure in the realm of pharmaceutical innovations. His work not only exemplifies the spirit of invention but also has the potential to make significant impacts on health and wellness.

This text is generated by artificial intelligence and may not be accurate.